Table 1.
Baseline Characteristics of the Tenofovir Adherence to Rapidly Guide and Evaluate Preexposure Prophylaxis and Human Immunodeficiency Virus Therapy (TARGET) Study Participants (N = 28)
| Adherence Arm | |||
|---|---|---|---|
| Characteristic | Low (n = 9) |
Moderate (n = 10) |
Perfect (n = 9) |
| Sociodemographic and clinical characteristics | |||
| Male, no. (%) | 3 (33) | 8 (80) | 5 (56) |
| Age, y | 38 (27–40) | 32 (28–33) | 34 (31–39) |
| Body mass index, kg/m2 | 23.1 (20.2–28.4) | 24.0 (22.1–25.1) | 20.2 (19.1–24.3) |
| Laboratory measures | |||
| White blood cells, cells/μL | 6700 (5200–7700) | 7950 (5800–8800) | 6500 (5900–6900) |
| Hemoglobin, g/dL | 13.3 (13.3–15.0) | 14.5 (14.4–15.2) | 12.4 (11.9–13.2) |
| eGFR (Cockcroft-Gault equation) | 108 (102–115) | 124 (98–132) | 91 (87–108) |
| Total bilirubin, mg/dL | 0.58 (0.47–0.79) | 0.84 (0.51–1.10) | 0.68 (0.35–0.76) |
| AST, U/L | 23 (21–24) | 26 (21–34) | 23 (21–24) |
| ALT, U/L | 17 (12–27) | 31.5 (20–46) | 16 (11–21) |
Data are presented as median (interquartile range) unless otherwise indicated.
Abbreviations: ALT, alanine aminotransferase; AST, aspartate aminotransferase; eGFR, estimated glomerular filtration rate.